A UK-based KOL outlines real-world management of neuroendocrine tumors, emphasizing organ-specific differences, treatment sequencing, and practical constraints within the UK system. The discussion covers use of systemic therapies across lines, considerations around access and licensing, and how clinical factors guide escalation beyond first-line care.

This interview was conducted on November 26, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.